PATENT CLAIM ANALYSIS

Application Number: 15926220
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-02
Patent Classification: ["514", "287000"]

Abstract:
The present invention relates to compositions and methods for treating of cancer. In some embodiments, the invention relates to the use of agents that can modulate a component in the CDX2-KLF4 signaling pathway to treat myelodysplastic syndromes (MDS), acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), adult T-cell leukaemia (ATLL), lymphoma, gastric cancer, multiple myeloma, or combinations thereof, or a condition associated with abnormal activity of the CDX2-KLF4 signaling pathway.

Claim (Index 23):
The method of  claim 21 , wherein the combination therapy comprises chemotherapy.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 90.0
- Lexical Diversity: 1.5614
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14506463', '11915257', '14356996', '15277857', '12249588']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6590865641042651
- 35 USC 102 Novelty (BERT): 0.5937623190494279
- Combined Prediction Score: 0.6525541395987814
- Mean Citation Score: 292.834862
- Max Citation Score: 586.82135
- Similarity Product: 380.9854897809536

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test